121 reports of this reaction
2.6% of all PROPAFENONE HYDROCHLORIDE reports
#6 most reported adverse reaction
DYSPNOEA is the #6 most commonly reported adverse reaction for PROPAFENONE HYDROCHLORIDE, manufactured by Actavis Pharma, Inc.. There are 121 FDA adverse event reports linking PROPAFENONE HYDROCHLORIDE to DYSPNOEA. This represents approximately 2.6% of all 4,618 adverse event reports for this drug.
Patients taking PROPAFENONE HYDROCHLORIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is a less commonly reported adverse event for PROPAFENONE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to dyspnoea, the following adverse reactions have been reported for PROPAFENONE HYDROCHLORIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 121 FDA reports for PROPAFENONE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 2.6% of all adverse event reports for PROPAFENONE HYDROCHLORIDE, making it a notable side effect.
If you experience dyspnoea while taking PROPAFENONE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.